Upsher-Smith La Patent-Cliff Exposure & CMS Drug Spending Portfolio

Upsher-Smith La (US): 13 reconciled FDA prescription therapies, $222.4M 2024 CMS Part D & Medicaid spend, and $14,929 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies13
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$222.4M
2024 Medicare Part D Spend$142.7M
2024 Medicaid Spend$79.7M
California HCAI SB 17 FilingsSpecialty launch notice ($14,929 intro WAC)